title: Oxcarbazepine in combination with Tiaprid in inpatient alcohol-withdrawal--a RCT.
abstract: BACKGROUND
  Oxcarbazepine (OXC), a derivative of Carbamazepine (CBZ), may represent a solution to metabolic and side effects of CBZ treatment due to the fact that renal excretion is its major route of elimination. The goal of the study is to compare the efficacy and tolerability of OXC/Tiaprid (TIA) combination therapy to the well established Clomethiazole (CLO) therapy in an inpatient setting.
  
  
  METHODS
  To investigate the efficacy of OXC/TIA in terms of lower alcohol withdrawal symptoms and better tolerability, 56 alcohol-dependent patients participated in a randomized open-label trial, where OXC/TIA and CLO treatments were compared.
  
  
  RESULTS
  Following admission, we observed that severity of alcohol withdrawal syndrome was comparable between OXC/TIA and CLO-patients. Overall tolerability was good. However, significantly more patients in the OXC/TIA-group (48.1%) displayed no AE compared to the CLO-group (24.1%). We found no significant differences between groups regarding total number of recorded adverse events (AEs).
  
  
  CONCLUSIONS
  OXC/TIA inpatient therapy proved to be as effective and participants demonstrated the same tolerance as with CLO. In medication-based alcohol withdrawal, OXC/TIA could have the potential to become a promising alternative for alcohol dependent patients unable to undergo inpatient withdrawal therapy with CLO. Our findings further indicate that it could be worthwhile testing OXC/TIA in alcohol withdrawal in daily care units and outpatient settings. This is an important question for national health care services, since outpatient therapy is more and more asked for as alternative to inpatient settings.
authors.affiliation: Department of Psychiatry, Psychotherapy and Psychosomatics, Teaching Hospital Sigmaringen, University of Tuebingen, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Croissant
authors.forename: S
authors.initials: S
authors.lastname: Loeber
authors.forename: A
authors.initials: A
authors.lastname: Diehl
authors.forename: H
authors.initials: H
authors.lastname: Nakovics
authors.forename: F
authors.initials: F
authors.lastname: Wagner
authors.forename: F
authors.initials: F
authors.lastname: Kiefer
authors.forename: K
authors.initials: K
authors.lastname: Mann
mesh_terms: D000328:Adult; D019973:Alcohol-Related Disorders / Q000188:drug therapy*; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002220:Carbamazepine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002719:Chlormethiazole / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007297:Inpatients; D008297:Male; D008875:Middle Aged; D000078330:Oxcarbazepine; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy*; D013976:Tiapamil Hydrochloride / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D002719:Chlormethiazole; D002220:Carbamazepine; D013976:Tiapamil Hydrochloride; D000078330:Oxcarbazepine